Tempest Therapeutics (TPST) Proxy filing summary

Executive summary

• A special meeting of stockholders was convened to vote on amending the Restated Certificate of Incorporation to replace supermajority voting requirements and allow stockholder action by written consent.

• The meeting was adjourned due to insufficient votes and will reconvene on October 14, 2026, to facilitate broader participation.

• 72.7% of outstanding shares were represented at the meeting, constituting a quorum.

Voting matters and shareholder proposals

• The main proposal seeks to amend the certificate to eliminate certain supermajority voting requirements and permit action by written consent.

• Approval requires at least 75% affirmative votes of all stockholders entitled to vote.

• No changes have been made to the proposal since the initial distribution.

• Proxies previously submitted remain valid unless revoked.

Board of directors and corporate governance

• Directors and executive officers are participating in the proxy solicitation process.

• Information about directors and executive officers is available in recent SEC filings.